The estimated Net Worth of Mark A. Burnett is at least $815 Тысяча dollars as of 14 November 2011. Mark Burnett owns over 100,000 units of ProPhase Labs Inc stock worth over $814,774 and over the last 14 years Mark sold PRPH stock worth over $0.
Sign up
Mark Burnett PRPH stock SEC Form 4 insiders trading
Mark has made over 2 trades of the ProPhase Labs Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently Mark bought 100,000 units of PRPH stock worth $87,000 on 14 November 2011.
The largest trade Mark's ever made was buying 100,000 units of ProPhase Labs Inc stock on 14 November 2011 worth over $87,000. On average, Mark trades about 7,700 units every 6 days since 2010. As of 14 November 2011 Mark still owns at least 301,768 units of ProPhase Labs Inc stock.
You can see the complete history of Mark Burnett stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at ProPhase Labs Inc
Over the last 15 years, insiders at ProPhase Labs Inc have traded over $6,868,501 worth of ProPhase Labs Inc stock and bought 2,996,691 units worth $4,189,802 . The most active insiders traders include Braden Michael Leonard, Ted William Karkus и James T Mccubbin. On average, ProPhase Labs Inc executives and independent directors trade stock every 98 days with the average trade being worth of $586,896. The most recent stock trade was executed by Ted William Karkus on 1 February 2023, trading 500,000 units of PRPH stock currently worth $300,000.
What does ProPhase Labs Inc do?
prophase labs is a diversified natural health medical science company. for more information visit us at www.prophaselabs.com.
What does ProPhase Labs Inc's logo look like?
Complete history of Mark Burnett stock trades at ProPhase Labs Inc
ProPhase Labs Inc executives and stock owners
ProPhase Labs Inc executives and other stock owners filed with the SEC include:
-
Ted William Karkus,
Chairman & CEO -
Monica Brady,
Chief Financial Officer -
Ted Karkus,
Chairman of the Board, Chief Executive Officer -
Monica Brady,
Chief Financial Officer -
Warren Hirsch,
Independent Director -
Louis Gleckel,
Independent Director -
Jason Barr,
Independent Director -
Sergio Miralles,
Exec. VP & Chief Information Officer of ProPhase Diagnostics -
Sam A. Beeler,
Chief Strategy Officer of Precision Medicine -
Jason Karkus,
Exec. VP & Co-COO -
Alice Lioi,
Exec. VP & Co-COO -
Mark S Leventhal,
Director -
Mark Shawn Frank,
Director -
James T Mccubbin,
Director -
Mark A. Burnett,
Director -
Braden Michael Leonard,
10% owner -
Guy J Quigley,
10% owner -
Robert V Jr Cuddihy,
Chief Operating Officer -
John De Shazo,
Director -
Jed Latkin,
Director -
Robert A. Jr. Morse,
CHIEF FINANCIAL OFFICER